L-carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats

Basic and Clinical Pharmacology and Toxicology

Volumn 106, Issue 4, 2010, Pages 296-301

  O'Brien, Daniel ^a   Chunduri, Prasad ^a   Iyer, Abishek ^a   Brown, Lindsay ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; COLLAGEN; DEOXYCORTICOSTERONE ACETATE; DRINKING WATER; INTERSTITIAL COLLAGENASE; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ARTICLE; ATTENUATION; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR FUNCTION; CELL INFILTRATION; CONTROLLED STUDY; DIASTOLE; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MITOCHONDRION; HEART MUSCLE FIBROSIS; HEART MUSCLE PERFUSION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; INFLAMMATORY CELL; ISOLATED HEART; LIPID PEROXIDATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY CHAIN; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; THORACIC AORTA; UNINEPHRECTOMY; VASCULAR DISEASE; VASCULAR RING;

ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; CARNITINE; DESOXYCORTICOSTERONE; ENDOTHELIUM, VASCULAR; HYPERTENSION; MALE; MALONDIALDEHYDE; MITOCHONDRIA; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; VENTRICULAR REMODELING; VITAMIN B COMPLEX;

RATTUS;

EID: 77949471906     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00480.x     Document Type: Article

References (39)

1. Tominaga H, Katoh H, Odagiri K, Takeuchi Y, Kawashima H, Saotome M et al. Different effects of palmitoyl-L-carnitine and palmitoyl-CoA on mitochondrial function in rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2008;295:H105-12.
2. Bremer J. Carnitine - metabolism and functions. Physiol Rev 1983;63:1420-80.
3. Carvajal K, Moreno-Sánchez R. Heart metabolic disturbances in cardiovascular diseases. Arch Med Res 2003;34:89-99.
4. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann NY Acad Sci 2003;1033:79-91.
5. Pauly DF, Pepine CJ. The role of carnitine in myocardial dysfunction. Am J Kid Dis 2003;41:S35-43.
6. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007;49:241-8.
7. Doggrell SA, Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 1998;39:89-105.
8. Ammarguellat F, Larouche I, Schiffrin EL. Myocardial fibrosis in DOCA-salt hypertensive rats. Effects of endothelin ETA receptor antagonism. Circulation 2001;103:319-24.
9. Callera GE, Touyz RM, Teixeira SA, Muscara MN, Carvalho MH, Fortes ZB et al. ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension 2003;42:811-7.
10. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodelling. Hypertension 2003;42:49-55.
11. Allan A, Fenning A, Levick S, Hoey A, Brown L. Reversal of cardiac dysfunction by selective ET-A receptor antagonism. Br J Pharmacol 2005;146:846-53.
12. Mirkovic S, Seymour A-ML, Fenning A, Strachan A, Margolin SB, Taylor SM et al. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol 2002;135:961-8.
13. Fenning A, Harrison G, Rose'meyer R, Hoey A, Brown L. L-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats. Am J Physiol 2005;289:1408-16.
14. Brown L, Duce B, Miric G, Sernia C. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J Am Soc Nephrol 1999;10:167-73.
15. Brown L, Ooi S-Y, Lau K, Sernia C. Cardiac and vascular responses in DOCA-salt hypertensive rats. Clin Exp Pharmacol Physiol 2000;27:263-9.
16. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC Jr, Cruickshank JM et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 2001;20:3-16.
17. Rosca MG, Vazquez EJ, Kerner J, Parland W, Chandler MP, Stanley W et al. Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylation. Cardiovasc Res 2008;80:30-9.
18. Puddu P, Puddu GM, Cravero E, Rosati M, Muscari A. The molecular sources of reactive oxygen species in hypertension. Blood Press 2008;17:70-7.
19. Esposito LA, Melov S, Panov A, Cottrell BA, Wallace DC. Mitochondrial disease in mouse results in increased oxidative stress. Proc Natl Acad Sci U S A 1999;96:4820-5.
20. Shibutani S, Takeshita M, Grollman AP. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 1991;349:431-4.
21. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta 2006;1757:509-17.
22. Massie BM, Schaefer S, Garcia J, McKirnan MD, Schwartz GG, Wisneski JA et al. Myocardial high-energy phosphate and substrate metabolism in swine with moderate left ventricular hypertrophy. Circulation 1995;91:1814-23.
23. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996;94:2837-42.
24. Yamashita H, Bharadwaj KG, Ikeda S, Park TS, Goldberg IJ. Cardiac metabolic compensation to hypertension requires lipoprotein lipase. Am J Physiol Endocrinol Metab 2008;295:E705-13.
25. Gülçin I. Antioxidant and antiradical activities of L-carnitine. Life Sci 2006;78:803-11.
26. Malone JI, Cuthbertson DD, Malone MA, Schocken DD. Cardio-protective effects of carnitine in streptozotocin-induced diabetic rats. Cardiovasc Diabetol 2006;5:2, doi:10.1186/1475-2840-5-2.
27. Gómez-Amores L, Mate A, Miguel-Carrasco JL, Jiménez L, Jos A, Cameán AM et al. L-carnitine attenuates oxidative stress in hypertensive rats. J Nutr Biochem 2007;18:533-40.
28. El-Beshlawy A, Youssry I, El-Saidi S, El-Accaoui R, Mansi Y, Maklouf A et al. Pulmonary hypertension in beta-thalassemia major and the role of L-carnitine therapy. Pediatr Hematol Oncol 2008;25:734-43.
29. Miguel-Carrasco JL, Mate A, Monserrat MT, Arias JL, Aramburu O, Vázquez CM. The role of inflammatory markers in the cardioprotective effect of L-carnitine in L-NAME-induced hypertension. Am J Hypertens 2008;21:1231-7.
30. Rajasekar P, Palanisamy N, Anuradha CV. Increase in nitric oxide and reductions in blood pressure, protein kinase C beta II and oxidative stress by L-carnitine: a study in the fructose-fed hypertensive rat. Clin Exp Hypertens 2007;29:517-30.
31. Jadhav A, Torlakovic E, Ndisang JF. Hemin therapy attenuates kidney injury in deoxycorticosterone acetate-salt hypertensive rats. Am J Physiol Renal Physiol 2009;296:F521-34.
32. Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol 2004;287:R1014-30.
33. Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ et al. Endothelin-1 increases vascular superoxide via endothelinA-NADPH oxidase pathway in low-renin hypertension. Circulation 2003;107:1053-8.
34. Viel EC, Benkirane K, Javeshghani D, Touyz RM, Schiffrin EL. Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 2008;295:H281-8.
35. Calvani M, Reda E, Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol 2000;95:75-83.
36. Callera GE, Tostes RC, Yogi A, Montezano AC, Touyz RM. Endothelin-1-induced oxidative stress in DOCA-salt hypertensive hypertension involves NADPH-oxidase-independent mechanisms. Clin Sci (Lond.) 2006;110:243-53.
37. de Sotomayor MA, Mingorance C, Rodriguez-Rodriguez R, Marhuenda E, Herrera MD. L-Carnitine and its propionate: improvement of endothelial function in SHR through superoxide dismutase-dependent mechanisms. Free Radic Res 2007;41:884-91.
38. Alvarez de Sotomayor M, Bueno R, Pérez-Guerrero C, Herrera MD. Effect of L-carnitine and propionyl-L-carnitine on endothelial function of small mesenteric arteries from SHR. J Vasc Res 2007;44:354-64.
39. Irat AM, Aktan F, Ozansoy G. Effects of L-carnitine treatment on oxidant/antioxidant state and vascular reactivity of streptozotocin-diabetic rat aorta. J Pharm Pharmacol 2003;55:1389-95.